Tag Archives: TRIPS

Indian Patents Ensure Wide Access to Drugs, Without Raising Prices

patent

Two recent studies on Indian drugs have shown that patent protection does not dramatically increase prices, but does ensure widespread access to life saving therapeutics. This research confirms that a weak patent environment slows drug availability and hinders treatment to many people in need. Data Shows Little Change in Indian Drug Prices after Implementing Stronger Patent System In a new report published by the National Bureau of Economic Research, scholars found that patented drugs did not Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

De-Mystifying Trade Agreements

shutterstock_13529329

To many people in our industry, international trade agreements may seem like esoteric documents that have little relevance to the day-to-day workings of a research-based, innovative enterprise. After all, aren’t these agreements more about the cross-border trade of big-ticket goods like autos and wheat than they are about new, cutting edge technologies? Well, actually no. Those who have been paying close attention know that these agreements define many of the underlying rules of the road Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

TRIPs Has Delivered: Patent Agreement Increases Drug Development

US Patent Application

The TRIPs (Trade Related Aspects of Intellectual Property) Agreement, effective in 1996, has resulted in multiple benefits for public health. The last blog post reviewed Progressive Economy’s finding of TRIPS at 20. One additional benefit not mentioned in the article is the explosion of molecules in clinical development. The World Intellectual Property Indicators – 2012 Edition reveals an overall growth in patent applications around the world. The report finds that patent applications “worldwide doubled from Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Is the Myriad Case Decision and/or the DOJ Brief TRIPS Compliant?

Judge Sweet seemed to dismiss Myriad’s constitutional taking and TRIPS claims by indicating: “Finally, Myriad’s suggestion that invalidating the patents-in-suit would constitute an unconstitutional taking in violation of the Fifth Amendment of the Constitution or a violation of the United States’ obligations under the Agreement on Trade-Related Aspects of Intellectual Property Rights (“TRIPS”) is unpersuasive. Myriad’s novel taking argument runs counter to a long history of invalidation of patent claims by the courts and is unsupported by legal Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , ,